Fresenius Kabi is seeking applicants for a new $100,000 U.S. research award to support the advancement of the therapeutic areas of photopheresis, and red cell exchange. “Fresenius Kabi along with its Fenwal subsidiary are committed to supporting innovative science that provides hope through the advancement of photopheresis and red cell exchange,” said William Cork, executive vice president and chief technology officer for the Fresenius Kabi Medical Devices division.   Photopheresis therapy invol...